Skip to contentO
Outlook Therapeutics, Inc.
O
OTLKOutlook Therapeutics, Inc. Q1 2019 · 10-Q
Revenue$1.07M$1.07M+38.3% vs Q1 2018 Net Income-$9.74M-$9.74MN/M vs Q1 2018 EPS Diluted-$1.00-$1.00N/M vs Q1 2018 Operating Income-$10,257,315N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR
Free Cash Flowderived-$10,017,808N/M Margins · derivedOperating margin-960.8%−548.8 pt vs Q1 2018
Net margin-912.5%−663.7 pt vs Q1 2018
ended Dec 31, 2018 · filed Feb 14, 2019 · 45 d after period end